T2C2 Capital

T2C2 Capital is a Canadian venture capital firm specializing in biotechnology investments. The firm focuses on identifying and commercializing technologies emerging from universities, research centers, and industry, aiming to transform innovative ideas into successful businesses. T2C2 Capital is involved in both early and late-stage venture investments, providing support from seed funding through subsequent financing rounds.

The firm's investment strategy emphasizes sectors such as biotechnology, healthcare, medical devices, pharmaceuticals, life sciences, therapeutics, biopharma, clinical trials, and product research. T2C2 Capital operates primarily within Canada, with a particular focus on the province of Quebec. The firm has a history of investing in companies like Aegera Therapeutics Inc., which raised US$10.7 million in a private round co-led by T2C2 Capital and other investors.

T2C2 Capital's mission is to identify business opportunities in universities, research centers, and industry, turning them into real businesses. The firm seeks outstanding science, high-quality entrepreneurs, intellectual property, and commercial potential as key elements for selecting projects. T2C2 Capital gets involved in the seed phase to support the continuation of research and to develop the business engineering of the project, participating with other investors in the financing of subsequent rounds.

T2C2 Capital is headquartered in Montreal, Quebec, Canada. The firm's contact information includes a phone number: +1 (514) 842-9849. For more information, visit their official website at http://www.t2c2capital.com.